Farooq Umar, Rasul Akhtar, Sher Muhammed, Qadir Muhammad Imran, Nazir Imran, Mehmood Yasir, Riaz Humayun, Shah Pervaiz Akhtar, Jamil Qazi Adnan, Khan Barkat A
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan.
Department of Chemistry, University of Sargodha, Sargodha, Pakistan.
Pak J Pharm Sci. 2020 Jan;33(1(Special)):449-457.
Topical candidiasis is a known skin fungal infection which is usually treated by conventional dosage forms such as cream, gel, emulgel which are having numerous adverse effects on skin. To overcome such disadvantages, different novel drug delivery systems have been considered. Polymer based nano-particulate systems have shown good skin penetration after topical application. Therefore, in the present study the main focus was on the pathology, pathogenesis, and consequently topical treatment of candidiasis. Nanogel containing miconazole have been prepared from the natural polymers i.e. gelatin and chitosan. The nanogel of miconazole (100 mg) nitrate was formulated by modified emulsification-diffusion technique and characterized for different parameters. From all the seven nanogel formulations named as F1 to F7, F1 (Gelatin and Chitosan in the percentage of 82.85 and 17.15 respectively) have been selected as model formulations. The reason behind that was as per ICH stability guideline, the formulations F1 was found optimum and stable. Miconazole nanogel formulations F1 also showed the maximum release i.e. 78 % approximately. XRD showed the formulated nanogel was in crystalline shape. In summary, the miconazole nanogel drug delivery systems have two main advantages i.e. they are topical preparation as well as nano sized. It can be postulated that nanogel may be a best approach to treat the fungal skin diseases.
局部念珠菌病是一种已知的皮肤真菌感染，通常采用乳膏、凝胶、乳胶等传统剂型进行治疗，这些剂型对皮肤有许多不良反应。为克服这些缺点，人们考虑了不同的新型药物递送系统。基于聚合物的纳米颗粒系统在局部应用后显示出良好的皮肤渗透性。因此，在本研究中，主要关注念珠菌病的病理学、发病机制以及相应的局部治疗。含咪康唑的纳米凝胶由天然聚合物即明胶和壳聚糖制备而成。采用改良乳化-扩散技术制备了100mg硝酸咪康唑纳米凝胶，并对其不同参数进行了表征。在所有七种名为F1至F7的纳米凝胶制剂中，F1（明胶和壳聚糖的比例分别为82.85%和17.15%）被选为模型制剂。其背后的原因是，根据ICH稳定性指南，F1制剂被发现是最佳且稳定的。咪康唑纳米凝胶制剂F1也显示出最大释放率，约为78%。X射线衍射显示所制备的纳米凝胶为晶体形状。总之，咪康唑纳米凝胶药物递送系统有两个主要优点，即它们是局部制剂且为纳米尺寸。可以推测，纳米凝胶可能是治疗真菌性皮肤病的最佳方法。
